News for Anixa Biosciences, Inc. (ANIX)

PR NewswireSAN JOSE, Calif., July 24, 2025 Patent Expands Immunogenic Coverage of α-Lactalbumin-Based Vaccine PlatformTechnology Addresses Substantial Unm

Anixa Biosciences (ANIX) revealed that the U.S. Patent and Trademark Office will grant U.S. Patent Number 12,370,244 on July 29, 2025. This patent encompasses s

On July 18, 2025, Arnold Baskies, a Director at Anixa Biosciences Inc (ANIX), purchased 5,000 shares of the company. Following this transaction, the insider now

Anixa Biosciences' breast cancer vaccine elicited targeted immune responses in 70% of patients. Click here to read an analysis of ANIX stock now.

On July 11, 2025, Titterton Lewis H jr, a Director at Anixa Biosciences Inc (ANIX), purchased 10,000 shares of the company. Following this transaction, the insi

On July 11, 2025, Amit Kumar, the CEO of Anixa Biosciences Inc (ANIX), purchased 5,000 shares of the company, according to a SEC Filing. This transaction increa

PR NewswireSAN JOSE, Calif., July 9, 2025 SAN JOSE, Calif., July 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX),

Anixa Biosciences (ANIX) is set to receive a crucial U.S. patent, numbered 12,357,593, from the United States Patent and Trademark Office on July 15, 2025. This

Anixa Biosciences (ANIX) to be issued U.S. Patent for ovarian cancer vaccine technology on July 15, 2025. The patent strengthens Anixa's intellectual pr

Does ANIXA BIOSCIENCES INC (ANIX) have what it takes to be a top stock pick for momentum investors? Let's find out.

PR NewswireSAN JOSE, Calif., May 19, 2025 SAN JOSE, Calif., May 19, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX),

PR NewswireSAN JOSE, May 12, 2025 SAN JOSE, May 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology

PR NewswireSAN JOSE, Calif., April 30, 2025 SAN JOSE, Calif., April 30, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: AN

Anixa Biosciences (ANIX) to present at H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025. The event will be held at Nasdaq World

PR NewswireSAN JOSE, Calif., April 14, 2025 SAN JOSE, Calif., April 14, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: AN

Anixa Biosciences (ANIX) receives a Notice of Allowance from the USPTO for its CAR-T technology patent. The patent is exclusively licensed to Anixa from

Anixa Biosciences (ANIX) has announced a significant milestone in its development of cancer treatment technologies, receiving a Notice of Allowance from the Uni

PR NewswireSAN JOSE, Calif., April 9, 2025 Patent Broadens Immunogenic Compositions for Preventive Vaccine ApproachSAN JOSE, Calif., April 9, 2025 /PRNewsw

Anixa Biosciences (ANIX) receives a Notice of Allowance from the USPTO for a new breast cancer vaccine patent. The patent covers immunization methods us